Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 02, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,000,000 ordinary shares of 25 pence each.
- Purchase Price: 1,462.73 pence per share.
- Treasury Shares Held: 128,658,000 shares (post-transaction).
- Shares in Issue: 5,829,256,704 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program authorized by shareholders at the Annual General Meeting on May 25, 2005. The company executed the purchase on December 02, 2005, and intends to hold the acquired shares in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the 1,000,000 share repurchase based on the disclosed price of 1,462.73 pence.
- Confirm the updated total share count (5,829,256,704 in issue) against subsequent filings.
- Check the company's remaining authorization for share buybacks under the May 25, 2005 shareholder resolution.